

3.(Amended) The suspension as defined in claim 1 wherein said lecithin is

5ub C } selected from the group consisting of a lecithin derived from soybean and a lecithin derived from egg.

[Please amend claim 4 as follows:]

4.(Amended) The suspension as defined in claim 1 wherein said hydrocolloid is selected from the group consisting of xanthan gum, a pectin, gelatin, guar gum, carrageenan, methylcelluloses, hydroxypropyl celluloses, gum arabic and a mixture of the foregoing hydrocolloids.

[Please amend claim 5 as follows:]

5ub C3 } 5 B5 } 5ub C4 } 6. (Amended) The suspension as defined in claim 1 wherein said surfactant is selected from the group consisting of cetylpyridinium chloride, polysorbate 80, sorbitan monostearate, a polyglycerol ester, a block copolymer of propylene oxide, ethylene oxide and a mixture of any of the foregoing surfactants.

[Please amend claim 6 as follows:]

6..(Amended) The suspension as defined in claim 1 wherein said stabilizer comprises said DOWICIL.

[Please amend claim 14 as follows:]

5ub C5 } 14.(Amended) A stable particulate suspension consisting essentially of, a nutrient selected from the group consisting of (a) an isoflavone, (b) lycopene, (c) lutein, (d) Coenzyme Q_n, where n is integer of 1 to 12; and (e) a mixture of any of the foregoing nutrients;

a nutrient stabilizer selected for the group consisting of (a') a hydrocolloid selected from the group consisting of xanthan gum, a pectin, gelatin, guar gum, carrageenan,

216
CS
cont
B
cont

methycelluloses, hydroxypropyl celluloses, gum arabic and a mixture of the foregoing hydrocolloids; (b) a surfactant selected from the group consisting of cetylpyridinium chloride, polysorbate 80, sorbitan monostearate, a polyglycerol ester and a mixture of any of the foregoing surfactants; (c) a DOWICIL and (d) a mixture of any of the foregoing stabilizers; and an aqueous solvent system.

REMARKS

Claims 1, 3-6 and 14 are presently in the subject application.

The specification has been amended in order to capitalize the trademark "DOWICIL" wherever it appears along with the its generic terminology.

Claims 7-13 have been cancelled without prejudicing Applicants' right to file a divisional application thereon.

Claim 2 has been cancelled without prejudice.

Claims 1, 3-6 and 14 have been amended to more fully define and more adequately protect Applicants' invention. The amendments neither add new matter nor raise any new issue and entry of these amendment is respectfully requested.

Claims 2 and 6 have been objected to for failure to capitalize "DOWICIL". Claim 2 has been cancelled without prejudice. Claim 6 has been amended to capitalize this trademark. Accordingly, it is respectfully submitted that claim 6 is no longer subject to an objection and allowance of claim 6 is requested.

Claim 3 is rejected under 35 U.S.C. § 112, second paragraph, because of improper Markush group language. This claim has been amended as suggested by the Examiner and is deemed no longer subject to a rejection under 35 U.S.C. § 112, second paragraph. Allowance of claim 3 is requested.

14